Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Author:

Kolstad Arne1,Laurell Anna2,Jerkeman Mats3,Grønbæk Kirsten4,Elonen Erkki5,Räty Riikka5,Pedersen Lone Bredo4,Loft Annika6,Bogsrud Trond Velde7,Kimby Eva8,Hansen Per Boye9,Fagerli Unn-Merete10,Nilsson-Ehle Herman11,Lauritzsen Grete Fossum1,Lehmann Anne Kristine12,Sundstrom Christer13,Karjalainen-Lindsberg Marja-Liisa14,Ralfkiaer Elisabeth15,Ehinger Mats16,Delabie Jan17,Bentzen Hans18,Schildt Jukka19,Kostova-Aherdan Kamelia20,Frederiksen Henrik21,Brown Peter de Nully4,Geisler Christian H.4

Affiliation:

1. Oncology, Oslo University Hospital, Oslo, Norway;

2. Oncology, Uppsala University Hospital, Uppsala, Sweden;

3. Oncology, Skåne University Hospital, Lund, Sweden;

4. Hematology, Copenhagen University Hospital, Copenhagen, Denmark;

5. Hematology, Helsinki University Hospital, Helsinki, Finland;

6. Positron Emission Tomography and Cyclotron Unit, Copenhagen University Hospital, Copenhagen, Denmark;

7. Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

8. Hematology, Karolinska University Hospital, Solna, Sweden;

9. Hematology, Herlev University Hospital, Herlev, Denmark;

10. Oncology, St. Olavs University Hospital, Trondheim, Norway;

11. Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden;

12. Oncology, Haukeland University Hospital, Bergen, Norway;

13. Pathology, Uppsala University Hospital, Uppsala, Sweden;

14. Pathology, Helsinki University Hospital, Helsinki, Finland;

15. Clinical Pathology, Copenhagen University Hospital, Copenhagen, Denmark;

16. Clinical Pathology, Skåne University Hospital, Lund, Sweden;

17. Pathology, Oslo University Hospital, Oslo, Norway;

18. Hematology, Aarhus University Hospital, Aarhus, Denmark;

19. Nuclear Medicine, Helsinki University Hospital, Helsinki, Finland;

20. Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden; and

21. Hematology, Odense University Hospital, Odense, Denmark

Abstract

Key PointsZ-BEAM/C did not improve outcome for patients in only PR or CRu before transplant. Positive PET before transplant and MRD after transplant predicted inferior PFS and OS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3